Stockreport

Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients

Kiromic BioPharma, Inc.  (KRBP) 
PDF Follow-up Scans Show Continued Stable Disease in First Patient CohortCompany to Apply for FDA Fast Track Designation HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. [Read more]